Aggressive Initial Management in Early Psoriatic Arthritis: Does Adding Golimumab to Methotrexate and Steroids Offer Superior Outcomes?
Posted inDermatology news Rheumatology

Aggressive Initial Management in Early Psoriatic Arthritis: Does Adding Golimumab to Methotrexate and Steroids Offer Superior Outcomes?

The GOLMePsA trial found no significant difference in disease activity at 24 weeks when adding golimumab to methotrexate and steroids for early PsA. However, the triple therapy significantly reduced the need for rescue corticosteroids, highlighting potential steroid-sparing benefits in early intervention.
PANLAR 2025 Recommendations for Polyarticular Juvenile Idiopathic Arthritis in Latin America — Practical, Evidence-Based Guidance for Resource-Variable Settings
Posted inAllergy & Immunology Clinical Updates news Rheumatology Specialties

PANLAR 2025 Recommendations for Polyarticular Juvenile Idiopathic Arthritis in Latin America — Practical, Evidence-Based Guidance for Resource-Variable Settings

PANLAR’s 2025 evidence-based recommendations for non-systemic polyarticular JIA emphasize early treat-to-target care using methotrexate, targeted escalation to biologics when needed, region-sensitive alternatives (leflunomide, triple nbDMARD therapy), and limited steroid bridging to improve outcomes in Latin America.